Bruker Corporation reported fourth‑quarter 2025 revenue of $977.2 million, a 0.2% decline from the $978.5 million earned in the same period a year earlier. The company’s non‑GAAP diluted earnings per share for the quarter were $0.59, missing the consensus estimate of $0.65 by $0.06, a 9.23% shortfall. The EPS decline was driven by a 15.7% non‑GAAP operating margin, down from 18.1% in Q4 2024, reflecting weaker demand and higher costs, including tariff and currency headwinds.
Full‑year 2025 revenue rose 2.1% to $3.44 billion, up from $3.37 billion in FY2024. However, organic revenue fell 3.7% year‑over‑year, underscoring the impact of lower volume and a less favorable product mix. Bruker’s non‑GAAP full‑year EPS was $1.83, down from $2.41 in FY2024, while GAAP earnings were a loss of $0.15 per share, largely attributable to impairment charges and restructuring costs.
Management maintained its fiscal 2026 outlook, projecting revenue of $3.57 billion to $3.60 billion and non‑GAAP EPS of $2.10 to $2.15. The guidance signals confidence in a gradual recovery, with the company emphasizing cost‑saving initiatives that should support margin expansion and double‑digit EPS growth in 2026.
Segment analysis shows the Scientific Instruments (BSI) division continued to drive demand, achieving a book‑to‑bill ratio above 1.0x for the second consecutive quarter, while the Energy & Supercon Technologies (BEST) segment secured strong multi‑year orders. These results reflect resilience in biopharma and industrial research markets, as well as improving semiconductor orders.
Headwinds remain pronounced, with academic funding constraints, tariff pressures, and currency fluctuations weighing on profitability. The company noted that these factors contributed to the margin compression seen in Q4. Conversely, tailwinds from a rebound in biopharma and industrial research, coupled with robust semiconductor demand, are expected to support future growth.
Investors reacted strongly to the EPS miss and margin contraction, signaling concern over profitability despite the revenue beat. The market’s focus on earnings and margin metrics highlights the importance of profitability indicators in assessing the company’s short‑term performance.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.